IDH1 and central nervous system cancer: Gliomas with IDH mutations (IDH-mutant) are generally associated with more favorable clinical outcomes and prolonged survival compared to IDH-wildtype gliomas, which tend to be more aggressive and confer a worse prognosis [2].